EUROEYES (01846) has released its interim results for the six months ended 30 June 2026, reporting a revenue of HK$454 million, up 20.5% year-on-year. The company recorded a loss attributable to shareholders of HK$13.561 million, marking a sharp reversal from the profit posted in the same period last year, with a loss per share of 4.254 HK cents.

According to the company's announcement, the significant expansion in presbyopia correction treatments, along with the consolidation of its Swiss business, were the key drivers behind the revenue growth during the period.